aMoon Fund

Founded 2016
Founders Yair Schindel


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 31
Average round size
The average size of a deal this fund participated in
Portfolio companies 29
Rounds per year 6.20
Lead investments 13
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Life Science
  • Medical Device

aMoon Fund appeared to be the VC, which was created in 2016. The company was established in Asia in Israel. The main department of described VC is located in the Ra'anana.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the aMoon Fund, startups are often financed by Lightspeed Venture Partners, Elron Electronic Industries, OurCrowd. The meaningful sponsors for the fund in investment in the same round are Lightspeed Venture Partners, Pacific 8 Ventures, OurCrowd. In the next rounds fund is usually obtained by Samsung NEXT, Oxford Finance LLC, Longliv Ventures.

The current fund was established by Yair Schnidel.

Considering the real fund results, this VC is 63 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2019.

Among the most successful fund investment fields, there are Medical Device, Big Data. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Israel. The fund has no specific favorite in a number of founders of portfolio startups. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight DayTwo, Medial EarlySign, CartiHeal.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Mobilion Systems

Life Science
$60M13 Jul 2021 Chadds Ford Township, Pennsylvania, United States

KAHR medical

$46M16 Jun 2021 Jerusalem, Jerusalem District, Israel

Sera Prognostics

Health Care
Medical Device
$100M28 Apr 2021 Salt Lake City, Utah, United States

Health Care
$63M15 Apr 2021 California, United States

Scipher Medicine

Alternative Medicine
Artificial Intelligence
Health Care
Health Diagnostics
$82M24 Mar 2021 Massachusetts, United States


Artificial Intelligence
Life Science
Machine Learning
$125M23 Mar 2021 Vancouver, Washington, United States

Ibex Medical Analytics

Artificial Intelligence
Health Diagnostics
Machine Learning
$38M09 Mar 2021 Tel Aviv-Yafo, Tel Aviv District, Israel

Viracta Therapeutics

$65M24 Feb 2021 California, United States

Viracta Therapeutics

$40M30 Nov 2020 California, United States
Eleos Health Raises $6M in Seed Funding

– Eleos Health is a Boston, MA- and Tel Aviv, Israel-based digital health startup.
– The company closed a $6M seed funding round.
– The round was led by aMoon Fund with participation from lool ventures, and Gandyr Group, alongside Arkin Holdings, Gaingels and former c-suite and executives from Google, MIT Media Lab, and Pegasystems.
– The company intends to use the funds for the expansion of sales, marketing, and solution delivery teams needed to meet the demand for enterprise software deployments across providers and payors.

Amylyx Pharmaceuticals Raises $135M in Series C Financing

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent aMoon Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: